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placebo treated control) in intima/media ratio paralleled by accelerated endothelial cover- 
age and reduced intimal call number. 
Conclusions: The combination treatment with VEGF-C adenovirus and STI571 led to a 
long-lasting inhibition of intimal thickening. Our study is one of the first successful exam- 
plas of gene therapy combined with pharmacological treatment and provides a novel 
principle to prevent intimal hyperplasia fter vascular intervention. 
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Graaorv M, Lanza. Dana R. Ahendschein, Michael J. Scott, Ralph W. Fuhrhop, David E. 
Schsrrar, Kerry Karukstis, Samuel A, Wicklins, Washington Universi~, St. Louis, 
Missouri, Harvey Mudd College, Claremont, California. 
Stect-based antiproliferative delivery systems create high lumen drug concentrations in 
order to achieve therapeutic dosage levels within the tunics media..High intima drug lev- 
els of antiproliferative agents induce inflammation, impede endothelial regrowth, and 
delay artedal wall healing. We have developed a tissue factor (TF)-targeted peramag- 
netic nanoparticle that specifically binds to vascular smooth muscle cells (VSMC) and 
provides local antiproliferative drug delivery. Methods: Anti-tissue factor (TF) nanoparti- 
cias incorporating 0 mol%, 0.2mo1% or 2.0 mol% paclitaxel or doxorubicin were targeted 
to VSMC in vitro for 30 minutes and cellular proliferation was determined 3 days later. 
Results: VSMC proliferation was decreased (p<0,05) 0%, 75% and 81% by TF-targeted 
paslitaxel nanoparticles (Fig) and by 0%, 59% and 72% for TF-targeted doxorubicin 
nanoparticias, respectively. Effective drug delivery depended on the interaction of the 
drug-iaclen anoparticia surface with the target cell membrane, which was facilitated by 
the ligand-surfaca ttachments. 
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Conclusion: TF-targeted paramagnetic nanoparticles can be employed to directly deliver 
antiproliferative therapy to VSMC in a new clinical paradigm that could circumvent he 
deleterious ide-effects often associated with drug-eluting stent-besed approaches. 
4:45 p.m. 
872-4 Decorln Overexpresslon In the Arterial Well Prevents 
Neolntime Formetlon and Collagen Accumulet lon 
Following Balloon Angloplasty 
Asim N, Cheema. Nafiseh Nili, Alan W, Barolet, Jacek Unda, Balplng Qiang, Mohammed 
R. Eskandadan, Frank J. Giordano, John Sparkes, Bradley H. Strauss, St. Michael's 
Hospital, Toronto, Ontario, Canada. 
Extracalluiar matrix (ECM) plays a cdtical role in the development of restenosis after bal- 
loon angiopiasty (BA). Collagen is the major ECM protein and its accumulation is an 
important mechanism of restenosis. In-vitro studies from our laboratory have shown that 
dacodn, a small proteoglycan, inhibits collagen synthesis in cultured smooth muscle 
cells. Therefore, we evaluated the in-vivo effects of decorin overexpression in the vessel 
wall. 
BA was performed in a double injury model of restenosis in rabbit carotid arteries. Aden- 
oviral-DNA constructs encoding for either betagaiactosidese (B-gal) or decorin were 
administered intraluminally at the time of 2nd injury. A third group (control) only recaivod 
2 balloon injuries without gene transfection. Animals were sacrificed at 10 weeks after 
2nd injury. The treated arteries (n=12 per group) were removed and analyzed for col- 
lagen content and by morphometry. 
The intimal area (mean:t:SD, mm 2) of dacofin group was 0.29-/-0.12 compared to 
0.42t-0.14 in the t3-gal and 0.48±O.16 in the control group (p<0.05, compared to control 
and =3-gal). Total collagen content (mean:l:SD, pg/OH proline per artedal segment) in the 
decofin group was 228198 compared to 343d:109 in the B-gel and 411+331 in the control 
group (p<0.04, compared to control and 6,gel). 
Adenoviral mediated decodn overexpression inhibits neointima formation and collagen 
accumulation after balloon injury. These findings suggest a possible therapeutic role for 
decorin in the treatment of restenosis after BA. 
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880-1 Three-Dimensional IVUS Amnment  of Edge Effects 
Following Drug-Elutlng Stent Implantetlon 
Toru Kataoka. Eberhard Grubs, Yasuhiro Honda, Karl E. Hauptmann, Yoshihiro Modno, 
Seung-Ho Hut, Paul G. Yock, Peter J. Fitzgerald, SCORE investigators group, Stanford 
University. Stanford, Cafifornia, Heart Center Siogburg, Siegburg, Germany. 
Drug-eluting stents produce a stdking reduction of nsointimal growth within the stant. 
However, potential edge effects have not been systematically investigated. The purpose 
of this study was to use sedal 3-D IVUS to evaluate the long-term vessel response at 
adjacent reference segments of the QUANAM QP2 (a taxol analogue)-eluting stent 
(DES) compared to bare metal stants (BMS). 
Methods: Sedal (baseline and 6-month follow-up) IVUS images of 69 stont edges in 40 
patients (20 DES; 20 BMS) were analyzed in SCORE, a randomized trial comparing DES 
vs. BMS. External elastic membrane (EEMA), plaque (PA), and lumen areas (LA) were 
measured at every 1 mm cross-section within 5 mm outside of both stant margins. Area 
changes (4) were computed as follow-up minus baseline. 
Results: Baseline lesion and procedural characteristics were similar in'the two groups. 
Overall, DES had a slightly greater mean APA at the stent edges than BMS (DES 
0.63±1.35 vs BMS 0.03d:1.01 mm 2, p=0.04). However, mean ~.LA was similar in the two 
groups (DES -0.31±1.25 mm 2 vs BMS -0.63+1.31 mm 2, ns) due to an increase in mean 
EEMA in DES (,~EEMA: DES 0.35~1.51 vs BMS -0.60±1.51 mm 2, p=0.01). Figure shows 
~,EEMA, ApA, and ,~LA over the stent edges. 
Conclusions: This 3-D IVUS analysis of SCORE revealed no evidence of negative edge 
effects following the QP2-eluting stent implantation as compared to bare metal stents. 
The preservation of edge lumen with the QP2-eluting stant was due to a prevention of 
vessel shrinkage, particularly at the distal reference. 
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880-2 Edge Effect Does Not Occur After Implantation of 
Sirollmus-Eluting Stents: A Three-Dimensional 
Intravascular Ultrasound Analysis From the RAVEL Trial 
Andrea S. Abizald. J. Eduardo Souse,, Pim de Feyter, Aiaxandra Abizald, Egon Wualfert, 
William Wijns, Marie C. Morice, Giulio Guagliumi, Antonio Colombo, Patrick Serroys, 
Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil, Lenox Hill Heart and 
Vascular Institute, Cardiovascular Research Foundation, New York, New York. 
Background: Edge lumen loss, the so-called "edge effect,' is one of the limitations of 
brechytherapy, especially after implanting beta-emitting stects. The purpose of the cur- 
rent analysis is to determine whether edge effects also occur after implantation of simli- 
mus-aluting stents. Methods: The RAVEL trial, a placebo-controlled randomized 
multicanter study, compared sirolimus-eluting (SE) Bx Velocity TM stants (Cypher TM) ver- 
sus uncoated Bx Velocity TM stents in 237 pts with single, de novo lesions in native coro- 
nary arteries. All patients received clopidogrel for a 2-month period. Serial volumetric 
intravascular ultrasound (IVUS) analysis was performed in 95 patients at 6 months fol- 
low-up. The volumetric analysis included 5mm long reference segments adjacent to the 
proximal and distal edges of the stent. Mean cross-sectional area results over the length 
of the reference segments are reported. Results: In pts treated with SE stents, there was 
